Xenon acne med fails mid-stage trial
Xenon Pharmaceuticals Inc <XENE.O> said on Friday it would abandon its acne drug, after it failed to meet the main goal in a mid-stage study. The drug, XEN801, which was tested against a placebo, did not induce a statistically significant effect in treating moderate to severe facial acne. [nGNXNQYPXa] The drug also failed to meet secondary endpoints, the company said. Other companies which are developing acne treatments include Dermira Inc <DERM.O>, Novan Inc <NOVN.O> and Foamix Pharmaceuticals Ltd <FOMX.O>. Acne is the most common skin condition in the United States, affecting up to 50 million Americans annually, according to the American Academy of Dermatology. Xenon is developing drugs for a host of other conditions, including epilepsy, cardiovascular disease and pain management.